Gastroesophageal Reflux Disease (GERD)

>

The HCPLive gastroesophageal reflux disease page is a comprehensive resource for clinical news and insights on GERD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for reflux disease, and more.

Latest News

Matthew Hoscheit, MD | Credit: Cleveland Clinic
Matthew Hoscheit, MD: Expanding the GERD Treatment Armamentarium with Vonoprazan

July 18th 2024

Vonoprazan (Voquezna), the first major innovation in GERD treatment in more than 30 years, is now FDA-approved for both erosive and non-erosive GERD.

FDA black and white logo | Credit: US Food and Drug Administration
Vonoprazan (Voquezna) Receives FDA Approval for Heartburn Associated with Non-Erosive GERD

July 18th 2024

Black and White FDA Logo | Credit: US Food and Drug Administration
FDA Accepts NDA for Vonoprazan (Voquenza) in Non-Erosive GERD

December 7th 2023

Vonoprazan for the Treatment of Erosive Esophagitis: A Randomized Controlled Trial
Vonoprazan for the Treatment of Erosive Esophagitis: A Randomized Controlled Trial

December 6th 2023

FDA approves VOQUENZA ® to treat Erosive Esophagitis
FDA Approves Vonoprazan to treat Erosive Esophagitis

November 1st 2023

More News

© 2024 MJH Life Sciences

All rights reserved.